Prolensa is an anti-inflammatory drug owned by Bausch And Lomb. This drug, which contains the active ingredient bromfenac sodium, was first authorized for market use on April 5, 2013. Prolensa is available in solution/drops;ophthalmic dosage forms. The drug holds a total of 9 patents, none of which have expired so far.
Currently, all patents on Prolensa are still active, with the last patent set to expire on November 11, 2033. Therefore, the generic version of Prolensa may become available after that date.
Prolensa is primarily used as a treatment for postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. The active ingredient, bromfenac sodium, is essential in providing relief from ocular inflammation. The drug can also be used for treatment to alleviate inflammation of the eye, as well as for treating ocular inflammation.
Prolensa holds 9 patents, none of which have expired. The final Prolensa patent is expected to run out on November 11, 2033, which would be the earliest possible date for the release of a Prolensa generic. Below are the details of the patents: